Results 41 to 50 of about 112,380 (305)

PARP inhibition attenuates acute kidney allograft rejection by suppressing cell death pathways and activating PI-3K-Akt cascade. [PDF]

PLoS ONE, 2013
BACKGROUND: Novel immunosuppressive therapy facilitates long term allograft survival, but acute tubular necrosis and ischemia-reperfusion during transplantation can compromise allograft function.
Karoly Kalmar-Nagy, Peter Degrell, Aliz Szabo, Katalin Sumegi, Istvan Wittmann, Ferenc Gallyas, Balazs Sumegi   +6 more
doaj   +1 more source

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma

Cell Reports, 2023
Summary: Ovarian high-grade serous carcinoma (HGSC) is the most common subtype of ovarian cancer with limited therapeutic options and a poor prognosis. In recent years, poly-ADP ribose polymerase (PARP) inhibitors have demonstrated significant clinical ...
Yuewei Xu, Sarah Spear, Yurui Ma, Marc P. Lorentzen, Michael Gruet, Flora McKinney, Yitao Xu, Chiharu Wickremesinghe, Madelen R. Shepherd, Iain McNeish, Hector C. Keun, Anke Nijhuis   +11 more
doaj   +1 more source

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. [PDF]

, 2017
Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing an urgent need to develop new treatment strategies. The liver is the most common site of metastasis.
Aplin, Andrew E., Cheng, Hanyin, Chua, Vivian, Davies, Michael A., Kageyama, Ken, Liao, Connie, Purwin, Timothy J., Sato, Takami, Terai, Mizue   +8 more
core   +2 more sources

PARP Inhibitors for Chemoprevention—Letter [PDF]

Cancer Prevention Research, 2014
We read with great optimism To and colleagues' ([1][1]) article about PARP inhibitors as effective chemopreventive strategy for treating homologous repair (HR)–deficient tumors. Their overarching conclusion stated in the discussion is that “…synthetic lethality (i.e., PARP inhibitor ...
Saswati N, Chand, Fernando F, Blanco, Masaya, Jimbo, Theodore N, Tsangaris, Massimo, Cristofanilli, Charles J, Yeo, Jordan M, Winter, Michael J, Pishvaian, Jonathan R, Brody   +8 more
openaire   +2 more sources

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer

Journal of Experimental & Clinical Cancer Research, 2019
Background The muscle invasive form of urothelial bladder cancer (UBC) is a deadly disease. Currently, the therapeutic approach of UBC is mostly based on surgery and standard chemotherapy.
Francesco Morra, Francesco Merolla, Daniela Criscuolo, Luigi Insabato, Riccardo Giannella, Gennaro Ilardi, Aniello Cerrato, Roberta Visconti, Stefania Staibano, Angela Celetti   +9 more
doaj   +1 more source

Defective DNA repair mechanisms in prostate cancer: impact of olaparib [PDF]

, 2017
The field of prostate oncology has continued to change dramatically. It has truly become a field that is intensely linked to molecular genetic alterations, especially DNA-repair defects.
De Felice, Francesca, Marampon, Francesco, Marchetti, Claudia, Musella, Angela, Tombolini, Vincenzo   +4 more
core   +2 more sources

PARP-1 dependent recruitment of the amyotrophic lateral sclerosis-associated protein FUS/TLS to sites of oxidative DNA damage [PDF]

, 2013
Amyotrophic lateral sclerosis (ALS) is associated with progressive degeneration of motor neurons. Several of the genes associated with this disease encode proteins involved in RNA processing, including fused-in-sarcoma/translocated-in-sarcoma (FUS/TLS ...
Adamson, Ahel, Amy Rotheray, Amé, Beli, Bertolotti, Chou, Da Cruz, Das, Dormann, Dormann, Duncan A. Q. Moore, El-Khamisy, Fernando Gómez-Herreros, Gabrielle J. Grundy, Gagné, Gardiner, Gitler, Hallier, Hanson, Hicks, Hoell, Johansson, Keith W Caldecott, Kino, Kleiman, Kleiman, Kleiman, Krietsch, Kuroda, Kwiatkowski, Lagier-Tourenne, Lagier-Tourenne, Lehtiö, Mackenzie, Majid Hafezparast, Malanga, Mastrocola, Masutani, Polo, Polymenidou, Rulten, Rulten, Ryan L. Green, Schwartz, Shieh, Stuart L. Rulten, Tan, Tan, Turner, Vance, Wang, Yang, Yang   +53 more
core   +1 more source

Hyperosmotic stress induces PARP1‐mediated HPF1‐dependent mono(ADP‐ribosyl)ation

FEBS Letters, EarlyView.
Sorbitol‐induced hyperosmotic stress rapidly induces reversible mono(ADP‐ribosyl)ation (MARylation) on PARP1 without the signs of genotoxic signaling. We show that PARP1 autoMARylation is HPF1 dependent and forms hydroxylamine‐resistant O‐glycosidic linkages.
Anna Georgina Kopasz, Mihály Mérey, Rebeka Vásárhelyi, Ramóna Pék, Victor Imburchia, László Henn, Adrián Kószó, Nicholas D. Lakin, Ivan Ahel, Sébastien Huet, Ágnes Czibula, Gyula Timinszky   +11 more
wiley   +1 more source

SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer

Cell Death and Disease
Poly (ADP-ribose) polymerase (PARP) inhibitors are effective in cells with homologous recombination (HR) deficiency, including BRCA1/2 mutation. However, PARP inhibitors remain a therapeutic challenge in breast and ovarian cancer due to inevitably ...
Mithun Ghosh, Min Sil Kang, Nar Bahadur Katuwal, Sa Deok Hong, Seong Min Park, Seul-Gi Kim, Seung Ryeol Lee, Yong Wha Moon   +7 more
doaj   +1 more source

Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance

Gynecologic Oncology Reports
Objective: Platinum-free interval (PFI) is the period from the end of platinum-based chemotherapy to the date of recurrence. If the PFI is > 6 months, a platinum-based chemotherapy rechallenge is considered; however, its efficacy after poly adenosine 5 ...
Takehiro Nakao, Kenichi Harano, Masashi Wakabayashi, Yoichi Naito, Hiroshi Tanabe, Toru Mukohara   +5 more
doaj   +1 more source